Eukaryotic initiation factor 5B: A new player for the anti-hepatitis C virus effect of ribavirin?

Medical Hypotheses

Volumn 79, Issue 4, 2012, Pages 471-473

  Galmozzi, E ^a   Aghemo, A ^a   Colombo, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; INITIATION FACTOR; INITIATION FACTOR 2; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 3; INITIATION FACTOR 5B; MESSENGER RNA; METHIONINE TRANSFER RNA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL STRESS; COMPLEX FORMATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHESIS; INTERNAL RIBOSOME ENTRY SITE; MOLECULAR MODEL; NONHUMAN; PROTEIN PHOSPHORYLATION; REPLICON; RIBOSOME; RNA INTERFERENCE; RNA TRANSLATION; TRANSLATION INITIATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG SYNERGISM; EUKARYOTIC INITIATION FACTOR-2; EUKARYOTIC INITIATION FACTORS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MODELS, BIOLOGICAL; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; RIBAVIRIN;

BACTERIA (MICROORGANISMS); EUKARYOTA; HEPATITIS C VIRUS;

EID: 84866001193     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.06.026     Document Type: Article

References (27)

1. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. PEG-interferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
3. Aghemo A., Rumi M.G., Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010, 7(9):485-494.
4. Tam R.C., Pai B., Bard J., Lim C., Averett D.R., Phan U.T., et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999, 30(3):376-382.
5. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118(2):346-355.
6. Feld J.J., Lutchman G.A., Heller T., Hara K., Pfeiffer J.K., Leff R.D., et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010, 139:154-162.
7. Wray S.K., Gilbert B.E., Noall M.W., Knight V. Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res 1985, 5:29-37.
8. Maag D., Castro C., Hong Z., Cameron C.E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001, 276(49):46094-46098.
9. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000, 6(12):1375-1379.
10. Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001, 98(12):6895-6900.
11. Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002, 76(17):8505-8517.
12. Lanford R.E., Chavez D., Guerra B., Lau J.Y., Hong Z., Brasky K.M., et al. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001, 75(17):8074-8081.
13. Mori K., Ikeda M., Ariumi Y., Dansako H., Wakita T., Kato N. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. Virus Res 2011, 157(1):61-70.
14. Kapp L.D., Lorsch J.R. The molecular mechanics of eukaryotic translation. Annu Rev Biochem 2004, 73:657-704.
15. Das S., Maitra U. Functional significance and mechanism of eIF5-promoted GTP hydrolysis in eukaryotic translation initiation. Prog Nucleic Acid Res Mol Biol 2001, 70:207-231.
16. Pestova T.V., Shatsky I.N., Fletcher S.P., Jackson R.J., Hellen C.U. A prokaryotic like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev 1998, 12(1):67-83.
17. Locker N., Easton L.E., Lukavsky P.J. HCV and CSFV IRES domain II mediate eIF2 release during 80S ribosome assembly. EMBO J 2007, 26(3):795-805.
18. Terenin I.M., Dmitriev S.E., Andreev D.E., Shatsky I.N. Eukaryotic translation initiation machinery can operate in a bacterial-like mode without eIF2. Nat Struct Mol Biol 2008, 15(8):836-841.
19. Pestova T.V., Lomakin I.B., Lee J.H., Choi S.K., Dever T.E., Hellen C.U. The joining of ribosomal subunits in eukaryotes requires eIF5B. Nature 2000, 403(6767):332-335.
20. Pisareva V.P., Hellen C.U., Pestova T.V. Kinetic analysis of the interaction of guanine nucleotides with eukaryotic translation initiation factor eIF5B. Biochemistry 2007, 46(10):2622-2629.
21. Carr S.F., Papp E., Wu J.C., Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993, 268(36):27286-27290.
22. Roll-Mecak A., Cao C., Dever T.E., Burley S.K. X-Ray structures of the universal translation initiation factor IF2/eIF5B: conformational changes on GDP and GTP binding. Cell 2000, 103(5):781-792.
23. Zhou S., Liu R., Baroudy B.M., Malcolm B.A., Reyes G.R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003, 310(2):333-342.
24. Rosenfeld A.B., Racaniello V.R. Components of the multifactor complex needed for internal initiation by the IRES of hepatitis C virus in Saccharomyces cerevisiae. RNA Biol 2010, 7(5):596-605.
25. Guo J.T., Sohn J.A., Zhu Q., Seeger C. Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology 2004, 325(1):71-81.
26. Robert F., Kapp L.D., Khan S.N., Acker M.G., Kolitz S., Kazemi S., et al. Initiation of protein synthesis by hepatitis C virus is refractory to reduced eIF2-GTP-Met-tRNA(i) ternary complex availability. Mol Biol Cell 2006, 17(11):4632-4644.
27. Shimoike T., McKenna S.A., Lindhout D.A., Puglisi J.D. Translational insensitivity to potent activation of PKR by HCV IRES RNA. Antiviral Res 2009, 83(3):228-237.